carbocyclic 2,3,4,6-tetra-O-benzyl-α-D-glucopyranose | 162119-25-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: carbocyclic 2,3,4,6-tetra-O-benzyl-α-D-glucopyranose
• 英文别名: 2,3,4,6-tetra-O-benzyl-5a-carba-α-D-glucopyranose；(1S,2S,3S,4R,5R)-2,3,4-tris(benzyloxy)-5-(benzyloxymethyl)-cyclohexanol；2,3,4,5-tetra-O-benzyl-5a-carba-α-D-glucopyranose；(1S,2S,3S,4R,5R)-2,3,4-tris(phenylmethoxy)-5-(phenylmethoxymethyl)cyclohexan-1-ol
• CAS: 162119-25-7
• 化学式: C₃₅H₃₈O₅
• 分子量: 538.684
• InChiKey: NJRAMLDONBHEDS-IXNRCNHTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  57.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  carbocyclic 2,3,4,6-tetra-O-benzyl-α-D-glucopyranose 在 正丁基锂 、 20 % Pd(OH)2/C 、 氢气 、 戴斯-马丁氧化剂 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 68.17h， 生成 4-{3-[(3aS,4S,5aR,9aR,9bR)-2,2,8,8-tetramethylhexahydro[1,3]dioxolo[4',5':3,4]benzo[1,2-d][1,3]dioxin-4-yl]benzyl}phenol
  参考文献：
  名称：

  C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  摘要：

  C-Aryl 5a-carba-beta-D-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the substituents on the two benzene rings resulted in enhanced hSGLT2 inhibition activity and extremely high hSGLT2 selectivity versus SGLT1. Using the created superimposed model, the reason for the high hSGLT2 selectivity was speculated to be that additional substituents occupied a new space, in a different way than known inhibitors. Among the tested compounds, the ethoxy compound 5h with high hSGLT2 selectivity exhibited more potent and longer hypoglycemic action in db/db mice than our O-carbasugar compound (1) and sergliflozin (2), which could be explained by its improved PK profiles relative to those of the two compounds. These results indicated that 5h might be a promising drug candidate for the treatment of type 2 diabetes. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.053
• 作为产物：
  描述：

  [(1R,2R,3S,4R,5S)-2,3,4-Tris-benzyloxy-5-(tert-butyl-dimethyl-silanyloxy)-cyclohexyl]-methanol 在 四丁基氟化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 carbocyclic 2,3,4,6-tetra-O-benzyl-α-D-glucopyranose
  参考文献：
  名称：

  令人惊讶的细菌核苷酸转移酶在 1-磷酸氨基葡萄糖转化中的选择性

  摘要：

  了解碳水化合物结合的分子决定因素以及寻找化学和生物化学上更稳定的糖衍生物和基于碳水化合物的疗法的动力导致合成了各种用硫或碳代替糖苷氧的类似物。相比之下，环氧取代对糖的构象和酶耐受性的影响在很大程度上被忽略了，部分原因是难以获得这些类似物。在此，我们报告了最常见的天然存在的 1-磷酸糖、1-磷酸葡萄糖的碳环形式的首次合成，以及其对细菌和真核糖核苷酸转移酶的评估。与真核酶的结果相反，1-磷酸卡巴葡萄糖作为细菌酶的底物，提供碳环尿苷二磷酸葡萄糖。该结果证明了此类糖基转移酶抑制剂和稳定活化糖模拟物的第一个化学酶促策略，用于与糖基转移酶及其糖基受体共结晶。酶之间转换的这种差异也表明在体内使用糖核苷酸转移酶来转化糖基转移酶抑制剂的前药形式的可能性。此外，我们报告了几种微波辅助反应，包括用钯进行五分钟的费里尔重排，加速碳环糖的合成以供进一步研究。该结果证明了此类糖基转移酶抑制剂和稳定活化糖模拟物的第一个

  DOI：

  10.1021/ja045522j

文献信息

• Synthesis and Evaluation as Glycosidase Inhibitors of Carbasugar-Derived Spirodiaziridines, Spirodiazirines, and Spiroaziridines
  作者：Peter Kapferer、Véronique Birault、Jean-François Poisson、Andrea Vasella

  DOI：10.1002/hlca.200390178

  日期：2003.6

  irreversible inhibitor of the β-glucosidase from Caldocellum saccharolyticum and a weak reversible inhibitor of the α-glucosidase from yeast, but did not inhibit the β-glucosidases from almonds. The poorly stable aziridine 21 weakly inhibited the three enzymes. Similarly, 1-epivalidamine (pKHA=8.4) proved only a weak inhibitor. The known cyclopentylamine 34 (pKHA=7.9), however, is a micromolar inhibitor of these

  从有效氧胺A衍生的环己酮5制备了潜在的α-和β-葡萄糖苷酶抑制剂spirodiaziridines 6和9。5的三甲基甲硅烷基保护基对于以高收率形成6至关重要。氧化6得到7。所述diaziridine 6（对ķ HA = 2.6）和二吖丙因7不抑制β从杏仁葡糖苷酶，所述β从葡萄糖苷酶Caldocellum糖热厌氧杆菌，和α-酵母中的葡萄糖苷酶。N-苄基二氮丙啶9是α-葡萄糖苷酶的非常弱的抑制剂，但不抑制β-葡萄糖苷酶。为了观察弱抑制是由于二氮丙啶的碱度低还是由于几何因素所致，我们制备了螺氮丙啶21和25以及1-epivalidamine（32）。将已知的环己酮10甲基化并环氧化为16和17。16和17的叠氮基打开，甲磺酰化，LiAlH 4还原和脱保护得到氮丙啶21和25。1-Epivalidamine（32）由已知的氨基葡萄糖29制备。氮丙啶25（p K HA = 6.8）是来自糖化卡尔德
• Synthesis of pseudo-trehaloses: [(1,2, ,5)-2,3,4-trihydroxy-5-hydroxymethyl-1-cyclohexyl] d-glucopyranosides
  作者：Seiichiro Ogawa、Shigeki Yokoi、Noritaka Kimura、Yasushi Shibata、Noritaka Chida

  DOI：10.1016/0008-6215(88)84022-9

  日期：1988.10

  Abstract All the theoretically possible, foru diastereoisomeric pairs, α,α (2A and 2B), α,β (3A and 3B), β,α (4A and 4B), and β,β (5A and 5B), of pseudo-trehalose, composed of d -glucopyranose and pseudo- d - or l -glucopyranose, have been synthesised by coupling of the appropriately protected pseudo-α- (6) and -β- dl -glucopyranoses (9) with d -glucopyranose derivatives (10 and 11) in the presence

  摘要在理论上所有可能的伪对映体对，即α，α（2A和2B），α，β（3A和3B），β，α（4A和4B）和β，β（5A和5B）。由d-吡喃葡萄糖和伪d-或l-吡喃葡萄糖组成的海藻糖是通过将适当保护的伪α-（6）和-β-dl-吡喃葡萄糖（9）与d-吡喃葡萄糖衍生物（10）偶联而合成的11）在三甲基甲硅烷基三氟甲磺酸盐存在下。伪二糖的结构和绝对构型的阐明是基于其八乙酸盐的1H-nmr光谱和旋光度。假海藻糖均不抑制海藻糖酶。
• Chemoenzymatic syntheses of carbasugar analogues of nucleoside diphosphate sugars: UDP-carba-Gal, UDP-carba-GlcNAc, UDP-carba-Glc, and GDP-carba-Man
  作者：Kyung-Chang Seo、Young-Geol Kwon、Dae-Hee Kim、In-Sook Jang、Jin-Won Cho、Sung-Kee Chung

  DOI：10.1039/b821058f

  日期：——

  Chemoenzymatic syntheses of several NDP-carba-sugars have been successfully carried out, and these essential cofactor analogues are expected to be selective inhibitors of glycosyltransferase enzymes.

  几种NDP-碳水糖的化学酶合成已成功进行，这些重要的辅因子类似物预计将成为糖基转移酶的选择性抑制剂。
• Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080318874A1

  公开（公告）日：2008-12-25

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH 2 —, or —NH—; n is an integer selected between 0 and 1; R 6 and R 7 each independently is hydrogen or C 1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q 1 to Q 5 ; Ar 1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar 2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，如持久的药物活性、代谢稳定性和安全性；以及用于预防或治疗与高血糖相关的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是-O-、-CH2-或-NH-；n是在0和1之间选择的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选择的整数；Q在以下式Q1至Q5之间选择；Ar1是可选的取代芳基或可选的取代杂环芳基，但杂环芳基可以与芳香环或芳香杂环结合形成融合环；Ar2是可选的取代芳基或可选的取代杂环芳基），该化合物的前药物或任一药物学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US08048897B2

  公开（公告）日：2011-11-01

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH2—, or —NH—; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平和药物所需的良好特性，如持久的药物活性，代谢稳定性和安全性；以及用于预防或治疗由高血糖引起的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是—O—，—CH2—或—NH—；n是在0和1之间选定的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选定的整数；Q在以下公式Q1至Q5之间选定；Ar1是可选择取代的芳基或可选择取代的杂芳基，前提是杂芳基可以与芳香碳环或芳香杂环结合形成融合环；Ar2是可选择取代的芳基或可选择取代的杂芳基），该化合物的前药物或任一的药学上可接受的盐。还提供了一种药物，药物组合物或包含该化合物的类似物。